These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21042933)

  • 1. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
    Blum JL; Kohles J; McKenna E; Scotto N; Hu S; Odom D; Kaye JA; Glück S
    Breast Cancer Res Treat; 2011 Jan; 125(2):431-9. PubMed ID: 21042933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
    Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J
    Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
    Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
    Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
    Ambros T; Zeichner SB; Zaravinos J; Montero AJ; Ahn E; Aruna M; Kronish L; Mahtani RL; Vogel CL
    Breast Cancer Res Treat; 2014 Jul; 146(1):7-14. PubMed ID: 24899084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
    Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
    Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
    Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
    Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
    Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
    Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
    Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
    Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
    Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.